🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

11 recruiting trials

for Minimal Change Disease (MCD)

Nephrotic Syndrome Study Network NCT01209000n/a44 sites📍 Los Angeles📍 Palo Alto📍 San Francisco University of Michigan · Tests: Kidney Biopsy A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD) NCT07710157Phase 26 sites📍 Graz📍 Innsbruck📍 Vienna Medical University Innsbruck · Tests: Obinutuzumab Injection, Predniso(lo)ne Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease NCT05650619n/a1 site📍 Ann Arbor University of Michigan · Tests: Biospecimen collection, Data collection An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases NCT06664814Phase 21 site📍 Bethesda National Human Genome Research Institute (NHGRI) · Tests: ManNAc Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases NCT07614477Phase 22 sites📍 Beijing📍 Tianjin Everest Medicines (China) Co.,Ltd. · Tests: EVER001 A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis NCT07499700Phase 2, Phase 31 site📍 Beijing Bio-Thera Solutions · Tests: BAT4406F, Placebos The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) NCT03949972n/a12 sites📍 Cologne📍 Aachen📍 Berlin Prof. Dr. Paul Brinkkoetter · Tests: Biosampling Study of WAL0921 in Patients With Glomerular Kidney Diseases NCT06466135Phase 250 sites📍 Los Angeles📍 Denver📍 Tamarac Walden Biosciences · Tests: WAL0921, Placebo A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease NCT06500702Phase 279 sites📍 Birmingham📍 Orange📍 San Francisco Sanofi · Tests: frexalimab, brivekimig, rilzabrutinib, placebo Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases NCT05003986Phase 247 sites📍 Los Angeles📍 Wilmington📍 Miami Travere Therapeutics, Inc. · Tests: Sparsentan, Sparsentan, Sparsentan NEPTUNE Match Study NCT04571658NA16 sites📍 Atlanta📍 Chicago📍 Kansas City University of Michigan · Tests: Communication
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy